

CyGenics Ltd • Australia • Level 4 • 414 Lonsdale Street • Melbourne 3000
Phone 61 (0)3 9642 5580 • Facsimile 61 (0)3 9462 5581
Singapore • 600 North Bridge Road • #12-09/10 Parkview Square • Singapore 188778
Phone (65) 6238 0808 • Facsimile (65) 6295 1108 • www.cygenics.com



For Immediate Release

CyGenics Strengthens Global Growth with Key Appointment

10th JANUARY 2005 – Leading global stem cell technology and immunotherapy company, CyGenics, Ltd. (ASX: CYN), announced that it had appointed an industry veteran, Alberto J. Bautista, to help drive its global expansion, especially in key markets such as the United States and Asia.

Mr Bautista will take on the role of Senior Consultant, Global Alliances & Corporate Development, reporting to the Group CEO. Utilising his industry background, extensive contacts and expertise, he will provide strategic advice and support as CyGenics expands globally. He will also facilitate high level discussions with a view towards mergers and acquisitions, and provide guidance in organisational structure and staffing.

Mr. Bautista brings significant industry knowledge to the company, as a veteran of Baxter International for nearly 30 years. NYSE-listed Baxter had sales in 2003 of US\$8.9 billion. He has worked for Baxter in several countries on four continents, most recently as a Vice President with its Japan office, where he was responsible for US\$300 million in sales. From 1997 to 2001, he was President of Baxter Healthcare Asia, with responsibilities for Baxter across Asia. From 1992 to 1997, he was responsible for four Baxter businesses in this region, tripling the company's sales in those five years.

Mr. Bautista graduated with a bachelors in industrial engineering from the University of the Philippines, and holds a masters in Management from the Sloan School of the Massachusetts Institute of Technology.



“CyGenics is looking to expand its presence in several key markets across the globe,” said Chris Fullerton, Chairman, CyGenics. “Mr. Bautista is a valuable addition to the team. With his great expertise and experience, and unparalleled contacts in the industry, we will achieve our goals more effectively.”

About CyGenics

CyGenics is a stem cell technology and immunotherapy company focused on the development and commercialisation of stem cell-related products, services, applications and technologies. From its headquarters in Australia, CyGenics operates three divisions: Singapore-based CordLife (tissue banking services, in particular, cord blood banking) and Cell Sciences (consumable cell culture products), and Cytomatrix (cell therapeutics and technology development), based in the USA. CyGenics is listed on the Australian Stock Exchange, under the symbol CYN. For more information, please visit www.cygenics.com.

For more information, please contact:

Ronald Hee
Corporate Communications &
Marketing Manager
CordLife Pte Ltd
600 North Bridge Road,
#12-09/10, Parkview Square,
Singapore 188778, Singapore
Tel : +65 6238 0808
Fax : +65 6295 1108
Mobile: +65 9061 9098
Email: rhee@cordlife.com

Rod Nockles
Director
Financial & Corporate Relations
Level 20,
114 William Street
Melbourne Victoria 3000
Australia
Tel: +61 3 9670 7996
Fax: +61 3 9670 3883
Mobile: +61 (0) 419 691 323
E-mail: r.nockles@fcr.com.au